Boston Scientific Corporation BSX
reports positive results from two trials evaluating new, innovative
drug-eluting stent (DES) technologies, which are emerging treatment options
for coronary heart disease. Data from the first human use NG PROMUS Clinical
Trial evaluating the safety and effectiveness of the Promus PREMIER™
Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year
follow-up data from the EVOLVE Trial comparing the safety and effectiveness of
the SYNERGY Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium
Coronary Stent System to the PROMUS Element™ Stent System were presented today
at the annual EuroPCR Scientific Program in Paris.
The NG PROMUS Clinical Trial evaluated the clinical and angiographic outcomes
for the Promus PREMIER Stent System at 30 days. John Ormiston, M.D., of Mercy
Angiography, Auckland City, New Zealand is the primary investigator for the
trial and presented data at the conference.
"The Promus PREMIER Stent demonstrated excellent safety and effectiveness with
zero percent target lesion revascularization and stent thrombosis," said Dr.
Ormiston. "In addition, the rate of technical success, the primary endpoint
of the trial, was very high at 99.2 percent. The Promus PREMIER Stent System
truly is a major step forward in stent technology."
The Promus PREMIER Stent System features the only customized stent
architecture of its kind providing strength without compromising flexibility.
An enhanced low-profile delivery system with a shorter, more visible tip,
dual-layer balloon and Bi-Segment™ inner lumen catheter is designed to
facilitate precise stent delivery across challenging lesions.
Two-year follow-up data from the EVOLVE Trial were also presented today at
EuroPCR by Professor Ian Meredith, director of MonashHeart, at Monash Medical
Centre in Melbourne, Australia. The primary clinical and angiographic
endpoints of this non-inferiority study, which compares the SYNERGY Stent to
the PROMUS Element Stent, have already been published.
"The clinical results of the SYNERGY Stent in EVOLVE continue to impress with
respect to safety and efficacy. At two years, we see no increase in the 1.1
percent target lesion revascularization (TLR) and zero percent stent
thrombosis rates that we observed in the full-dose SYNERGY Stent at one year,"
said Professor Meredith. "Interestingly, the difference in TLR between the
PROMUS Element Stent at 6.1 percent and the SYNERGY Stent at 1.1 percent is
approaching statistical significance (p=0.07). This is encouraging, as it
supports our hypothesis that the bioabsorbable polymer coating could provide a
long term benefit over durable polymer coated DES."
The SYNERGY Stent features a bioabsorbable PLGA polymer and everolimus drug
combination to create a low initial weight, ultra-thin, uniform coating that
is applied to the abluminal (outer) surface of the stent. The proprietary
PLGA polymer completes absorption shortly after drug elution ends at three
months, leaving only a bare platinum chromium stent. This technology provides
the same level of restenosis reduction as a conventional everolimus-eluting
stent while potentially offering faster and more complete vessel healing after
stent implantation, which could reduce the required duration of post-procedure
dual antiplatelet therapy.
"The Promus PREMIER and SYNERGY Stent Systems are the latest additions to our
growing pipeline of drug-eluting stent technologies," said Kevin Ballinger,
president, Interventional Cardiology, Boston Scientific. "These innovations
reflect our commitment to interventional cardiologists and the patients they
serve."
Coronary heart disease is a narrowing of the vessels that supply blood and
oxygen to the heart. Recent statistics from the European Heart Network and
the European Society of Cardiology show it is the single most common cause of
death in Europe accounting for 1.8 million deaths in Europe per year.
Patients living with coronary heart disease, also known as coronary artery
disease, may experience pain, shortness of breath and fatigue. They may also
be at risk for a heart attack. One treatment option is the placement of a
stent in the artery to help keep it open and allow the blood to flow more
freely.
The Promus PREMIER and SYNERGY Stents have CE Mark approval. In the United
States and Japan, they are investigational devices and are limited by
applicable law to investigational use only and are not available for sale.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in